Sera from immunocompromised people are excluded. Those submitted for testing for antibody to HIV and hepatitis B infection were excluded until 1996. Since then, to provide as complete a sample as possible for a viral hepatitis survey, laboratories have been asked to include these sera, flagging them appropriately. Laboratories are also asked to exclude recent repeat sera from the same individual.
For each serum, the age (or date of birth if available), sex, date of specimen and laboratory number are entered on a data sheet in the collecting laboratory. Sera and the accompanying documentation are forwarded to Preston PHL where each serum is assigned a unique identity number and the laboratory numbers removed so that the patients are no longer identifiable. This irrevocably unlinks the serum from any patient identifying data. Sera are stored at -20°C in dedicated freezers at Preston PHL. The data sheet is then forwarded to CDSC where the information is entered onto a central database.
Each year target numbers of sera (stratified by age and sex) are collected in the age groups 0-24 years. Every five years (1986/7, 1991 and 1996) sera are collected across the entire age range (although any sera provided in the intermediate years from older age groups are not discarded). Figure 2 shows the number of sera collected each year by age group. For each survey the required number of samples for each stratum (e.g. age group) are randomly selected from those available. The identification numbers are sent to Preston PHL where the majority of the testing (largely automated since 1994) is performed. Results are downloaded directly from the auto-analyser and sent to CDSC in computer files, where they are incorporated into the database and analysed.
Laboratory tests
Until 1992 sera were tested using haemagglutination inhibition (HI) (for measles) and radial haemolysis (for mumps and rubella), SEROLOGICAL SURVEILLANCE IN ENGLAND AND WALES 363 Figure 1 Public health laboratories contributing sera to Public Health Laboratory Service (PHLS) serological surveillance programme with enzyme immunoassays (EIA) being used to resolve sera giving a low concentration of specific IgG. Plaque reduction neutralization would be the test of choice for measles and mumps, but it is not suitable for testing large numbers of sera as it is time-consuming and relatively expensive. Moreover, measles haemagglutinating antigen and primate red blood cells became increasingly difficult to obtain. Since EIA had commercially produced reagents and benefited from automation, they became the most attractive option. It was therefore necessary to identify sensitive and specific EIA, which also enabled quantitative assessment of antibody levels. This was to provide discrimination at low concentrations of antibody, which may not provide complete protection. In 1993, suitable assays were selected following evaluation of many EIA and comparisons with previously used tests (measles; 12 mumps and rubella [unpublished results]). These were: measles, Rubeola-IgG, Gull Laboratories, Utah; mumps, Mumps IgG, Human, Weisbaden; and rubella, Captia Select Rubella G, Trinity Biotech, Dublin. Quantification is achieved by calibrating the optical density reading for each test serum against a standard curve, which is calculated from dilutions of a standard serum included on every test plate.
Results
Four tables describe the surveys, their results and implications, and the resulting actions. The latter may be further surveys or investigations or, as has happened on a number of occasions, changes in the UK national vaccination policy.
Measles, mumps and rubella
The measles, mumps and rubella surveys have been performed every year since 1986/87 ( 11 : the proportion in whom number of infections, but offered to pre-school children no antibody was detected fell at reduced circulation of virus (see above) should eliminate 2-6 years of age due to vaccination causes many who are not mumps infection (and all its but rose at 9-20 years as a result protected to remain susceptible complications, particularly in of reduced exposure to infection into adult life adults)
Rubella 22 1750, 1846 1994, 1995 In 5-10 year olds the proportion Vaccinating target groups leads to MR campaign should prevent without antibody fell from decreased susceptibility which future outbreaks in adults; 17.5% to 3.0% in turn should lead to a decrease without it susceptibility in males In 11-16 year olds the proportion in CRS aged 18-20 years would have fell from 6.2% to 1.0% in females Sex difference in prevalence risen above 20% and from 24.5% to 6.9% in males shows effect of previous selective vaccination campaign in 1994 to prevent a potential measles epidemic. 13, 14 As a result 7 million children aged 5-16 years were vaccinated in November 1994, 92% of all children in this age group. The impact on immunity to measles and rubella in the target populations was confirmed by surveys using samples taken before and after the campaign. 15 Following this, and the subsequent introduction of a second dose of MMR vaccine in 1996, the incidence of measles, mumps and rubella is low. It will be important to continue serological surveillance to monitor antibody prevalence, particularly in cohorts not vaccinated in the campaign (young adults and young children). Table 2 provides details of serological surveys of other vaccine preventable diseases. The survey performed for diphtheria demonstrated the speed with which the sera can be accessed, tested and the results analysed in response to emerging and reemerging disease threats (in this case diphtheria in the former Soviet Union). The hepatitis B surveys are an example of seroprevalence studies that complement disease incidence data and improve the understanding of disease epidemiology. These confirmed the low prevalence of hepatitis B infection in the UK 16, 17 and informed the decision not to implement a universal hepatitis B vaccination programme at present.
Other vaccine preventable diseases

Other infections
Surveys of other infections provide examples of how the incidence of infection can be estimated from age-specific prevalence of antibody. For infections with no long-term trends in their incidence, the age-specific incidence of infection (averaged over epidemic and non-epidemic years) can be estimated from the rate of decrease with age in the proportion of samples that are antibody negative. 18 A survey of antibody to parvovirus B19 enabled the age-specific incidence of infection to be estimated from which an estimate of the average risk of infection in pregnancy was derived. 19 The availability of archived sera is particularly valuable in investigating infections with long-term trends in their incidence (Table 3 ). For example, testing two cohorts of sera from 10-14 year olds collected 8 years apart has demonstrated a decline in the prevalence of infection with herpes simplex virus type 1 (HSV-1) (paper in preparation). This is caused by a decline in the incidence of infection in childhood and may contribute to changes in the epidemiology of genital herpes in adults.
Current and proposed surveys
The European Sero-Epidemiology Network (ESEN) is a 3-year project funded by the European Union and co-ordinated by CDSC. Its aim is to standardize the results of serological surveys in participating countries (Table 4) . 20 Once survey results are directly comparable, the impact of different national vaccination programmes on the respective populations may be assessed. This enables the strengths and weaknesses of the different vaccination schedules across the European Union to be identified.
Another current survey is assessing the extent of hepatitis C infection outside of known risk groups in England and Wales. Other proposed projects will exploit the serum archive to investigate changes in the prevalence of antibody to hepatitis A, Helicobacter pylori and Toxoplasma gondii between 1986 and 1996. The incidence of infection over this period in different age groups will be estimated by comparing the prevalence in equivalent birth cohorts (e.g. 30-34 year olds in 1986 with 40-44 year olds in 1996).
Discussion
Collection of sera
The sera used in this programme are not a random sample of the population, rather they are derived from residual blood samples obtained for diagnostic and screening tests. Women tend to be over-represented, presumably because of attendance for antenatal care. However, this over-representation is controlled for when selecting samples for testing from those available. It is also possible to use other data to estimate the sera's representativeness. For example, the prevalence of antibody to measles, mumps and rubella observed in 2-4 year olds by serological surveillance is that expected from coverage data and vaccine seroconversion rates. 15, 21, 22 The UK has a well-developed NHS with free access to health care for all. This limits the selection bias for UK residual sera, which is likely to be less than that for residual sera obtained in countries where access to health care is more limited. Furthermore, the sera have the advantages of being cheap and easy to obtain. Importantly they also avoid additional patient discomfort, particularly in young children. In view of the comprehensive diagnostic service that each laboratory offers, substantial differences in the reasons for which sera were submitted are unlikely, either over time or between laboratories. Therefore valid regional Smaller surveys suggest low prevalence-this needs Estimate incidence of infection over a 10-year to be confirmed in a large survey of adult population period Helicobacter 5000, 1986/87, Routes of transmission, the incidence of infection and Prevalence of infection is needed to estimate pylori (P) 5000 1996 the prevalence in the general population are unknown the cost of treatment and control programmes Toxoplasma 5000, 1986/87, T gondii is a serious complication of immunosuppression Determining the prevalence of infection will gondii (P) 5000 1996 and acute infection in pregnancy can lead to the birth enable the need for an antenatal screening of a severely disabled infant programme to be evaluated 24 ) surveys have been conducted using sera specifically donated by people randomly sampled from the population. This has the advantage of allowing detailed risk factor information to be obtained, but any gain in the representativeness of the sera comes at considerable financial cost. There is also no guarantee that the sera will be representative because of the potential for participation bias. Even follow up of non-responders cannot completely eliminate or correct for this bias.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
The major limitation of the programme in England and Wales is the lack of any data on ethnic group or country of birth. This is particularly problematic when studying diseases that are far more prevalent in other countries, e.g. hepatitis B. One solution would be to conduct occasional cross-sectional surveys on a smaller scale in which the requisite demographic information was collected.
The relatively simple methodology of the serological surveillance programme in England and Wales makes it transferable to other populations and countries. In countries with less developed health care infrastructures, alternative sources of sera could include those taken in accident and emergency departments.
Interaction with mathematical modelling
The interaction of serological surveillance with mathematical modelling has been particularly fruitful: surveys have provided better baseline data for mathematical models, which have been used to interpret the results of later serological surveys. The force of infection (the rate at which susceptibles acquire infection) 18 can be estimated from the age-specific antibody prevalence in an unvaccinated population, provided there is no long term trend in the incidence of infection. Contact rates between age groups, which can be estimated from the age-specific force of infection in an unvaccinated population, are fundamental parameters of mathematical models of disease transmission, 25 and reflect the potential for transmission of infection within the population.
Introduction of vaccination will change the prevalence profile (the age-specific prevalence of antibody) and the force of infection in a population, but not the contact rates (although, over long periods of time, contact rates may be affected by social changes within a population). Contact rates derived from pre-vaccination prevalence profiles can therefore be used to interpret the profiles obtained after vaccination is introduced. 14 Each serological profile can be summarized by a single parameter: the reproduction number, R. R is the number of secondary cases produced by a typical primary case; thus potential for an epidemic exists if R is greater than one. R is determined by the level of susceptibility in each age group and the contact rates within and between age groups. The sensitivity of R to the contact rates can also be explored. This method was applied to the serological results for measles, predicting a potential measles epidemic 14 that was prevented by the 1994 national vaccination campaign.
Interaction with other surveillance programmes
Comprehensive surveillance of vaccine preventable infections requires data from several sources. Serological surveillance complements but cannot replace surveillance of vaccine coverage and disease incidence (both clinical diagnoses and laboratory confirmed cases). For example, serological surveillance cannot rapidly detect changes in vaccination coverage, which can only be achieved by direct monitoring of coverage itself. Similarly, it cannot identify disease outbreaks or short term trends in disease incidence. However, disease incidence data yield little information on the epidemiology of infection if many infections are asymptomatic (especially if the proportion asymptomatic changes with age) or are clinically misdiagnosed. Furthermore, the absence of cases in a population reveals little about the potential for cases in future. Therefore, serological surveys are an important element of the surveillance of vaccination programmes.
Influence on vaccination policy
Serological surveys provide baseline data on the distribution of immunity to infection within a population. They are particularly valuable for evaluating the need for and the planning of new vaccination programmes and supplementary measures such as mass vaccination campaigns. Identifying the cohorts most susceptible to infection enables the intervention to be targeted to achieve maximum effect with the available resources.
The serological surveillance programme in England and Wales has directly influenced national vaccination policy. Examples include the 1994 measles and rubella campaign; the introduction of a second dose of MMR at 4 years of age; 26 and the decision not to implement a universal hepatitis B vaccination programme. As vaccination programmes succeed in eliminating infections, monitoring immunity of the population through serological surveys will assume even greater importance to ensure a scientific basis for decisions about national vaccination policy.
